Stem Cell and Regenerative Clinics Marketed for Aging

What FDA has said

• Approved stem cell products. The only FDA-approved stem cell products consist of blood-forming cells from umbilical cord blood, approved for disorders that affect blood production, not for other uses. [1]
• Not approved for many conditions. FDA says none of the regenerative products it discusses (stem cells, exosomes, fat-derived stromal vascular fraction, cord blood, Wharton's jelly, amniotic fluid) is approved for orthopedic conditions, neurological disorders, heart or lung disease, chronic pain or fatigue. [1] Because the only approved stem cell products are the cord blood ones, none is approved for aging.
• Exosomes. In December 2019 FDA reported serious adverse events in patients in Nebraska treated with unapproved products marketed as containing exosomes, and said clinics claiming exosomes fall outside drug and biologic rules are wrong. [2]
• Harms FDA cites. For illegally marketed products: blindness, tumor formation, neurological events, bacterial infections including life-threatening blood infections, reactions at the collection and injection sites, unwanted immune responses, cells growing into unintended tissue, and contamination. [3]
• Registries and registrations. FDA warns that listing on clinicaltrials.gov or a firm's FDA registration does not mean a product is legally marketed. It also says patients charged for such products outside a clinical trial are likely being offered a product illegally. [3]
• Asking about oversight. FDA's exosome notice advises patients to ask whether FDA has reviewed the treatment and to ask for the IND number, the Investigational New Drug application number that identifies FDA-overseen research. [2]

Laws and enforcement change, and this is not legal advice; these pages were read on 2026-10-22 and carry dates from 2019 to 2021.

How large is the marketplace?

Researchers who tracked US direct-to-consumer stem cell businesses found the number of new websites at least doubled each year from 2009 to 2014, then grew by roughly 90 to 100 new sites a year through 2016, while FDA warning letters were limited. [4] A related essay describes hundreds of clinics marketing unproven and unlicensed stem cell interventions. [5] This is older data and does not describe the market today.

What the research shows for aging frailty

Frailty (low reserve, slowness and weakness) is not the same as general "anti-aging," but it is where the aging-specific stem cell trials are.

• 2017 phase 2 trial. In 30 people with a mean age of about 75 with frailty, an intravenous infusion of donor mesenchymal stem cells at two amounts was compared with placebo. The main outcome was safety: no treatment-related serious adverse events at one month. Walking test, physical performance and a lung measure improved in the lower-amount group only, and the authors called for larger trials. [6]
• 2026 phase 2b trial. In 148 people with frailty, donor mesenchymal stem cell infusion raised six-minute walk distance versus placebo by 63.4 m at month 9 (a statistically significant difference), while the month-6 difference was not significant. [7] One author is chief scientific officer of, and holds equity in, the company developing the cell product. [7]

Label: promising but limited for frailty in carefully run, regulated trials; insufficient evidence for general anti-aging; marketing claim for most clinic offerings. Study cells were manufactured products used under trial oversight, which is not the same as what an unregulated clinic provides. Whether frailty trial results hold up is something larger studies must settle. For stem cells in more detail see regenerative research: stem cells, exosomes and PRP, and for the regulatory picture by product see regulatory status of regenerative products.